J Drugs Dermatol. 2022 Aug 1;21(8):897-899. doi: 10.36849/JDD.6888.
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of targeted biologic agents offers safe, effective options for children with moderate-to-severe skin and nail disease. A few are now Food and Drug Administration (FDA)-approved for children. J Drugs Dermatol. 2022;21(8):897-899. doi:10.36849/JDD.6888.
银屑病，一种慢性炎症性皮肤疾病，影响约 2%的儿童。一小部分儿童的指甲孤立受累，对外用治疗有抗药性，可能导致残疾。针对生物制剂的开发为中重度皮肤和指甲疾病的儿童提供了安全有效的选择。少数已获得美国食品药品监督管理局（FDA）批准用于儿童。J 皮肤病学杂志。2022;21(8):897-899. doi:10.36849/JDD.6888.
